MPMatthieu Proust

Matthieu Proust

*This is an algorithmically generated author record based on publicly available information.

Matthieu Proust has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Alain Combes

    Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation , Paris

    1 shared publication
  • Alban Redheuil

    Sorbonne University, Department of Cardiovascular and Thoracic Radiology, Hôpital de la Pitié-Salpêtrière (AP-HP), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France; Sorbonne University, Biomedical Imaging Laboratory (LIB), INSERM, CNRS, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France

    1 shared publication
  • Alexander Breitenstein

    Department of Cardiology, University Heart Center, University Hospital Zurich , Raemistrasse 100, Zurich 8091

    1 shared publication
  • Ardan Muammer Saguner

    Department of Cardiology, University Hospital Zurich

    1 shared publication
  • Benjamin Bertin

    Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital La Pitié-Salpêtrière, Département de Cardiologie, INSERM UMRS 1166-ICAN, ACTION Study Group, F-75013 Paris

    1 shared publication
  • Charles Juvin

    Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Chirurgie Cardio-Thoracique , Paris

    1 shared publication

Latest Publications

  • Prognostic impact of pericardial effusion in patients with acute myocarditis

    by Matthieu Proust, Florent Huang, Michel Zeitouni, Nadjib Hammoudi, Marie Dupuy, Estelle Gandjbakhch, Philippe Charron, Alban Redheuil, Francesco Ravera, Benjamin Bertin, et al.

    Aims: Recent Guidelines of the European Society of Cardiology have introduced the concept of Inflammatory Myocardial and Pericardial Syndrome (IMPS), a unified entity encompassing both myocarditis and pericarditis. This framework reflects the continuum between these conditions in term of anatomy, shared aetiologies, and a common diagnostic approach. This study sought (i) to describe factors associated with pericardial involvement; (ii) to compare the outcomes of patients hospitalized for proven acute myocarditis (AM) with or without pericardial effusion; (iii) to identify the independent correlates of clinical outcome. Methods and results: This is an observational ambispective cohort study based on the AMPHIBIA registry (Assistance Publique—Hôpitaux de Paris/ACTION Study Group), including patients hospitalized for proven AM between August 2008 and December 2024 at La Pitié Salpêtrière Hospital, Paris, France. Patients were stratified into two groups based on the presence of pericardial effusion on admission transthoracic echocardiography, ranging from minimal effusions to tamponade. The main composite outcome was defined as the occurrence of all-cause death, temporary mechanical circulatory support, severe ventricular arrhythmia, and heart transplantation, at the longest follow-up, up to 7 years. A total of 581 patients with AM were included [follow-up 3.7 (1.3–7.3) years]. Among them, 134 (23%) patients presented with pericardial effusion and 447 (77%) patients without. Four independent variables were associated with pericardial effusion at admission: left ventricular (LV) dysfunction, immunological myocarditis, elevated CRP, and fever. The occurrence of the composite event was significantly higher in patients with pericardial effusion compared to those without [38.1% vs. 15.7%, hazard ratio (HR) 2.69, 95% confidence interval (CI) (1.88–3.86), P < 0.001]. This difference was observed regardless of pericardial effusion size. After multivariable analysis, pericardial effusion was independently associated with the main composite outcome [HR 1.99 (1.32–3.00), P < 0.001. Conclusion: This study characterizes the phenotypes and outcomes of patients hospitalized for an AM, with and without pericardial effusion. Pericardial involvement was associated with LV dysfunction, immunological myocarditis, elevated CRP, and fever and was linked to a markedly higher risk of the composite outcome, remaining an independent predictor of adverse events. Differentiating these two phenotypes may provide physicians with valuable guidance for managing therapy in these patients.


  • Open Access

    Electromagnetic interference during epicardial ablation in a patient with an extravascular implantable cardioverter-defibrillator and arrhythmogenic right ventricular cardiomyopathy: a case report

    by Matthieu Proust, Feifan Ouyang, Alexander Breitenstein, Firat Duru, Ardan M Saguner

    Background: Arrhythmogenic cardiomyopathy (ACM) is an inherited disease characterized by fibrofatty replacement, most often involving the right ventricle but potentially affecting the left or both ventricles. It predisposes to severe ventricular arrhythmia (VA). Differentiating ACM from athlete’s heart remains difficult, particularly in gene-elusive patients. Implantable cardioverter-defibrillators (ICDs) and catheter ablation are key therapeutic options. Epicardial ablation may be required for VA circuits inaccessible in an endocardial approach, but data on its feasibility in patients with extravascular ICD (EV-ICD) featuring a retrosternal lead is scarce. Case summary: A 42-year-old male athlete was admitted for syncope due to sustained ventricular tachycardia (VT) during exertion. Cardiac magnetic resonance imaging (CMR) showed a dilated right ventricle (RV) with wall akinesia and fibrosis involving the RV outflow tract. Genetic testing was negative. The diagnosis of borderline gene-elusive ACM was made. An EV-ICD was implanted for secondary prevention. Recurrent sustained VT prompted endocardial and epicardial ablation, which was feasible and successful, but radiofrequency energy application was hampered close to the retrosternal lead due to electromagnetic interference. Conclusion: This case highlights the diagnostic and therapeutic challenges of ACM in athletes. Epicardial ablation is feasible even with an EV-ICD, although electromagnetic interference may complicate ablation near the lead. High-level endurance exercise can induce ACM-like remodelling, creating phenotypic overlap with gene-elusive ACM. Early recognition, tailored ablation strategies, and appropriate device therapy are essential for the management of these patients.